key: cord-0912346-u64ig0lj authors: Assawasaksakul, T.; Sathitratanacheewin, S.; Vichaiwattana, P.; Wanlapakorn, N.; Poovorawan, Y.; Avihingsanon, Y.; Assawasaksakul, N.; Kittanamongkolchai, W. title: Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patients date: 2022-03-15 journal: nan DOI: 10.1101/2022.03.15.22272350 sha: d1dac74697d14c90bc1242235a7b809af6d42cb5 doc_id: 912346 cord_uid: u64ig0lj Abstract Objectives: To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. Methods: SLE and RA patients aged 18-65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before and day 15 after each booster vaccination. The third BNT162b2 booster was administered on day 1. Patients with suboptimal humoral response to the third booster dose (anti-receptor binding domain (RBD) IgG on day 15 < 2,360 BAU/mL) were given a fourth BNT162b2 booster on day 22. Results: Seventy one SLE and 29 RA patients were enrolled. The third booster raised anti-RBD IgG by 15 fold and patients with positive neutralizing activity against the Omicron variant increased from 0% to 42%. Patients with positive cellular immune response also increased from 55% to 94%. High immunosuppressive load and initial inactivated vaccine were associated with lower anti-RBD IgG titer. Fifty four patients had suboptimal humoral responses to the third booster and 28 received a fourth booster dose. Although anti-RBD IgG increased further by 7 fold, no significant change in neutralizing activity against the Omicron variant was observed. There were 2 severe SLE flares that occurred shortly after the fourth booster dose. Conclusions: The third BNT162b2 booster significantly improved humoral and cellular immunogenicity in SLE and RA patients. The benefit of a short interval fourth booster in patients with suboptimal humoral response was unclear. -The SARS-CoV-2 omicron variant (B.1.1.159) has multiple mutations that have resulted in greater escape from immune protection elicited by COVID- 19 vaccines. -More attenuated immune response to SARS-CoV-2 vaccination has been observed in patients with autoimmune rheumatic diseases. The additional third dose of SARS-CoV-2 vaccine has been recommended in immunocompromised populations. -Some immunocompromised patients have a suboptimal humoral response to a third booster dose. Factors associated with poor immune response have not been adequately studied. -Administration of more than 3 doses has been shown to enhance immune response in some severely immunocompromised patients. -The third BNT162b2 booster was well tolerated, and significantly improved both humoral and cellular immunogenicity in SLE and RA patients previously vaccinated with either inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines. -High intensity of immunosuppressive therapy and initial inactivated vaccine were associated with lower humoral immune response to the third BNT162b2 booster. -Administration of a fourth BNT162b2 booster in poor humoral immune responders may not offer additional protection against the omicron variant, and flares were observed in SLE patients. -This study supported a third BNT162b2 booster dose administration in SLE and RA patients to enhance immune protection against the Omicron variant. -Patients who receive a high dose of immunosuppressive therapy or initial inactivated vaccine could be unprotected from SARS-CoV-2 infection. Benefits and risks of additional boosters or second generation of SARS-CoV-2 vaccine should be further studied. To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022 Seventy one SLE and 29 RA patients were enrolled. The third booster raised anti-RBD IgG by 15 fold and patients with positive neutralizing activity against the Omicron variant increased from 0% to 42%. Patients with positive cellular immune response also increased from 55% to 94%. High immunosuppressive load and initial inactivated vaccine were associated with lower anti-RBD IgG titer. Fifty four patients had suboptimal humoral responses to the third booster and 28 received a fourth booster dose. Although anti-RBD IgG increased further by 7 fold, no significant change in neutralizing activity against the Omicron variant was observed. There were 2 severe SLE flares that occurred shortly after the fourth booster dose. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 15, 2022. The third BNT162b2 booster significantly improved humoral and cellular immunogenicity in SLE and RA patients. The benefit of a short interval fourth booster in patients with suboptimal humoral response was unclear. The newly emerged B. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 15, 2022. ; In patients with autoimmune rheumatic diseases, a more attenuated immune response to SARS-CoV-2 vaccination has been observed 5 . According to a recent study, a third dose of mRNA 1273 vaccine significantly increased anti-receptor binding domain (RBD) titer in transplant recipients compared to placebo. However, in approximately half of the patients who received a booster, the anti-RBD titer remained low (<100 U/mL) 6 . Clinical factors associated with the immunogenicity in immunosuppressed populations have not been adequately studied. Several booster doses may be required to achieve adequate immune protection 7 . The safety and risk of disease flare associated with repetitive vaccination in patients with autoimmune rheumatic diseases remain unknown. We aimed to evaluate safety and immunogenicity of the third and fourth BNT162b2 booster doses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients previously vaccinated with either adenoviral vector, inactivated or heterogenous adenoviral vector/mRNA regimens. Factors associated with humoral immune response after the third booster dose were also evaluated. This is a prospective, single arm, open-labeled study, investigating the safety and immunogenicity of third and fourth mRNA vaccine (BNT162b2, Pfizer-BioNTech) booster doses in SLE and RA patients who have previously been vaccinated with inactivated SARS-CoV-2 COVID-19 vaccine (CoronaVac or Sinopharm), adenovirus-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Procedures At baseline, demographic information, current medications, disease activity, and blood samples for immunogenicity analyses were collected. On day one, 30 ug of BNT162b2 was administered intramuscularly via the deltoid region. On day 15, blood samples were collected in order to assess immune responses. On day 22, those with suboptimal humoral response, defined as anti-RBD IgG less than 2,360 BAU/mL (16,503 AU/mL) after the third booster, were given the fourth BNT162b2 booster at . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; 30 ug. Blood sample collection for immune responses assessment was performed again on day 36 ( Figure 1 ). We chose the anti-RBD IgG (Abbott Diagnostics) cut-off value of 2,360 BAU/mL (16,503 AU/mL) as it corresponded to vaccine efficacy of 90% for wild-type 8 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022 Immunosuppressive treatments Due to various immunosuppressive treatment regimens used in our cohort, we adopted and modified the Vasudev score 9 to calculate the overall immunosuppressive load. One unit of immunosuppression was assigned for each of the following doses of immunosuppressive medications: prednisone 5 mg/day, mycophenolate mofetil(MMF) 500 mg/day, azathioprine 100 mg/day, cyclosporine 100 mg/day, tacrolimus 2 mg/day, leflunomide 10 mg/day and methotrexate 15 mg/week( Table 1 Continuous variables were expressed as mean (standard deviation) or mean (95% confidence interval (CI)). Antibody levels were presented as geometric mean titers (GMT) with 95% CI, or median with range when appropriate. Geometric means were computed by natural log transformation of the data points and calculating the mean . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.15.22272350 doi: medRxiv preprint and 95% confidence interval on the transformed data. The ln-transformed mean and 95% confidence interval were transformed back to the original scale. The Student's t-test was used to compare the differences between two groups. Multiple groups were compared using one-way ANOVA, followed by the Bonferroni post hoc test. Linear regression was used to test for associations. One hundred patients were enrolled with 71 having SLE and 29 having RA. All of the patients had stable disease. Ninety three percent of patients were women. The majority of SLE patients received MMF and the majority of RA patients received methotrexate. (Table 2) Because ADZ1222 was primarily administered to the elderly in Thailand, it was given to slightly over half of the RA patients (51.7%) who tended to be relatively older. Vaccine administration was more equally divided among SLE patients with 38% receiving inactivated vaccines, 36.6% receiving ADZ1222/ADZ1222 and 25.4% receiving AZD1222/BNT162b2. The inactivated vaccine had the longest interval . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) between the second and third booster doses because it was the first vaccine series available in Thailand. ( Table 2) Humoral immune responses following the third and fourth BNT162b2 booster doses. Anti-nucleocapsid antibodies were undetectable in all pre and post-booster serum samples indicating that no covid-19 infection occurred during the peri-booster period. The initial inactivated vaccine and high immunosuppressive load were associated with low anti-RBD IgG titer, even adjusting for other covariates including age, sex, diagnosis, and vaccine interval between the second and the third booster dose ( Table 3) . Figures 3a,b ,c illustrate the relationship between total immunosuppressive load and type of initial vaccine with anti-RBD IgG levels. The cellular immune response of 47 randomly selected patients was assessed before and 14 days after the third booster dose. Twenty one, 15 and 11 patients received inactivated vaccines, AZD1222/AZD1222 and AZD1222/BNT162b2 as initial vaccines, respectively. Thirty four patients (72%) had SLE and the rest had RA. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.15.22272350 doi: medRxiv preprint After a third booster, the proportion of individuals who had a positive ELISPOT test increased from 55% to 94%. Before a third booster, those who initially received inactivated vaccines had the lowest rate of positive ELISPOT test (31%), followed by AZD1222/AZD1222 (67%), and AZD1222/BNT162b2 (73%) (p = 0.05), which increased to 90%, 93%, and 100% after the third booster (p=0.4). The BNT162b2 boosters were well tolerated, and all reactions were mild and transient. The three most common reactions were injection site pain, fatigue and fever (supplemental figure 3) . Anti-RBD IgG levels did not differ between those without adverse reactions and those who had at least one reaction (p=0.4) Two SLE patients experienced disease flare after the fourth booster dose. One patient developed rapidly progressive glomerulonephritis from lupus nephritis 1 week after receiving the fourth booster vaccine. Mycophenolate mofetil also had been withheld a few months before the booster administration due to a history of multiple infections. The other developed severe thrombocytopenia 4 weeks after receiving a booster dose. The patient's disease had been inactive for several years and she had not been receiving immunosuppressive treatment prior to this episode of flare. As the Omicron variant continues to spread around the world and display increased immune escape potential, aggregating data to optimize immunization strategies in autoimmune rheumatic disease populations is crucial. This study found that a third . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022 booster, particularly those who received more intense immunosuppressive treatment or an inactivated vaccine in the initial vaccine series. By giving a fourth BNT162b2 booster to poor immune responders, anti-RBD IgG increased to a lesser extent compared to the third booster dose (7 fold versus 15 fold), possibly due to the short interval between the third and fourth booster 10 . Despite the increase of anti-RBD IgG, no discernible increase in neutralizing activity against the Omicron variant was observed. In addition, two SLE patients (7%) experienced severe flares shortly after receiving their fourth booster dose. Multiple studies have reported acceptable safety profiles in SLE patients after initial vaccine series [11] [12] . However, in an animal model, repeated exposure to the same antigen was shown to induce autoimmunity 13 . Given this uncertainty, the benefit of administering a short interval fourth booster dose should be balanced against the risk of disease activation. In terms of cellular immunity, a third BNT162b2 booster elicited T-cell responses in nearly all of our patients. Positive cellular immune response rates were comparable across initial vaccine types, even among those who received inactivated vaccines, which are known to induce lower a T-cell response 14 . Recent studies have demonstrated that while variants of concern can evade neutralizing antibodies, the cell-mediated immune response cross-reacted with the variants of concern 15-18 . It . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.15.22272350 doi: medRxiv preprint also confers resilient protection against severe disease as antibody titers wane overtime 19 . It should be noted that there were several limitations to this study. The findings are observational and based on a small sample size, so they should be interpreted with caution. The results may not be generalizable to other autoimmune rheumatic conditions, other immunosuppressive regimens such as B-cell depletion therapy, or initial mRNA vaccine series. The immunosuppressive load calculation was adapted from the prior study which was arbitrarily determined. In conclusion, this study demonstrated that the third BNT162b2 booster was well tolerated and significantly improved humoral and cellular immunogenicity in SLE and RA patients. The intensity of immunosuppressive therapy and the type of initial vaccine appear to affect the humoral immune response to the third booster. In poor humoral responders, a fourth BNT162b2 booster administered at a short interval may not provide additional protection against the omicron variant. Our finding that severe flares were observed in SLE patients after the fourth booster is also cause for caution and additional research on the appropriateness of a fourth booster and the timing of such booster in our population. BNT162b2 (lot number 30125BA) used in this study was supplied by the Department of Disease Control, Ministry of Public health with support of Dr Wisit Prasitsirikul, Deputy director of Bamrasnaradura Infectious Disease Institute. The authors thank . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. Table 1 : Immunosuppressive load calculation scale modified from Vasudev score (9) . One unit of immunosuppression was assigned to the corresponding doses of agents. Immunosuppression unit . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022 (11) Data expressed as mean (SD) unless otherwise indicated. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis; SLEDAI = systemic lupus erythematosus disease activity index; DAS = disease activity score; CDAI = clinical disease activity index for rheumatoid arthritis; TNF = tumor necrosis factor . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 15, 2022. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.15.22272350 doi: medRxiv preprint Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases -Version 3 Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases Published Online First Self-organized criticality theory of autoimmunity Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination The T cell immune response against SARS-CoV-2 Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months T cell responses to SARS-CoV-2 spike crossrecognize Omicron Immunological mechanisms of vaccineinduced protection against COVID-19 in humans